Page 1909 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

1336 Index

Crystalloid versus Hydroxyethyl Starch Decisional capacity and surrogate decision vasopressin-induced skin necrosis,
Trial (CHEST), 929 making, 126–127 1286, 1286f
CTLA4-IG inhibition, use of, in critically ill Decisions to limit treatment, 127–128 cutaneous adverse drug reactions,
patient, 1252–1253 determinations of death, 128–129 1287–1290
Cutaneous adverse drug reaction, 1281, 1281f, documentation, 129–130 hypersensitivity syndrome/drug reaction
1282f, 1283ft, 1284 institutional protocols and supports, 128 with eosinophilia and systemic
classification of, 1281–1284, 1283t legal responsibility and vicarious symptoms, 1289–1290, 1290t
Cutaneous necrotizing venulitis, 1294 liability, 129 Stevens-Johnson syndrome and toxic
Cyanide, 1214–1215 risk management of, 130 epidermal necrolysis, 1287–1289,
Cyclic antidepressants, 1215–1216 Decision Support System (DSS), 55 1287f, 1288t, 1289t
Cyclophosphamide, 897, 899 Decompartmentalization, lung injury and, dermatoses precipitated by drugs,
use of, in critically ill patient, 1251 444–445 1280–1287
Cyclosporine, 1089 Decompression illness, 1320–1321, 1320t cutaneous adverse drug reactions,
CYP2C9 Polymorphism, 1236 Decompressive craniectomy, 1134–1135 1281, 1281f, 1282f, 1283ft
CYP2C19 Polymorphism, 1236 complications of, 816 epidemiology of adverse drug
CYP2D6 Polymorphism, 1235 Decreased left ventricular systolic reactions, 1281
CYP2E1 Polymorphism, 1236 contractility, 270–273, dermatoses precipitated by infection,
Cystic fibrosis, bronchial artery 271f, 272t 1296–1299
embolization and, 216 Deep cervical fascial space infections, bacterial, 1296
Cysts, renal, 700–701 678–679, 679f, 680ft, 681t infective endocarditis, 1299,
Cytokines, 565 Deep enteroscopy, 1021 1299f, 1300f
Cytomegalovirus (CMV), 670–671, 928 Deep fungal infections, 1303–1304, meningococcemia, 1298–1299,
infections due to, 636, 1106 1303f, 1304t 1299f, 1300ft
Cytopathic hypoxia, 565 Deep sulcus sign, 505, 506f necrotizing fasciitis, 1296–1297, 1297f
Cytotoxic chemotherapy, infection in patients Deep vein thrombosis (DVT), 221 pseudomonas bacteremia, 1298, 1298f
receiving, for malignancy, 600–625 in burn patients, 1187 staphylococcal scalded skin syndrome,
cancer patients in ICU, 601, 602t prophylaxis in surgical and trauma 1297, 1298f
deficits in host defenses related to cancer patient, 1067 toxic shock syndrome, 1297, 1297t
chemotherapy, 601–605, 602f, 605f Defects, learning from, 34, 35t fungal infections, 1303–1304
infection prevention in neutropenic Defibrillation, aspects of, 171–172 deep fungal, 1303–1304, 1303f, 1304t
host, 622–624 Deiodinases, 987 disseminated candidiasis, 1303
infections and bacterial pathogens causing Delayed afterdepolarization, 278 medical dermatoses, 1290–1296
neutropenic fevers, 605–606 Delirium, 112, 829 bullous pemphigoid, 1292, 1292f
infection syndromes in patients undergoing in intensive care unit, 756–763 edema bullae, 1295–1296, 1296f
cytotoxic chemotherapy, 615–622, Diagnostic and Statistical Manual of erythroderma, 1293, 1293ft
617f, 619f, 620f Mental Disorders (DSM-IV) on, graft-versus-host disease,
neutropenic fever, 606–615 756, 756t 1294–1295
Cytotoxic edema, 794 monitoring for, 759–760, 760t pemphigus vulgaris, 1290–1292, 1291f
Cytotoxic (type II) reactions, 1283 pathophysiology, 758–759, 759f psoriasis, 1292–1293, 1292f
Cytotoxic therapy, immunosuppressive prevalence and subtypes, 756–757 purpura, 1294
effects of, 603–605 prognosis following, 760–761, 761f selected dermatoses
risk factors, 757–758, 757t, 758f miliaria, 1304, 1304f
D strategies for prevention of, 761–762 pressure ulcers, 1304
Dabigatran, 288 treatment of, 762–763 viral infections, 1300–1302
Damage-associated molecular patterns Dementia, 829 herpes simplex, 1300, 1300ft, 1301f
(DAMPs), 552 Dengue fever, 717–718, 734, 736–737 human immunodeficiency virus,
Damage control orthopaedic treatment, early Dengue hemorrhagic fever, 734, 736–737 1302, 1302t
total care versus, 1175 Denis three-column theory of spinal smallpox, 1302
Dapsone, 632 instability, 1138 varicella zoster, 1300–1302, 1301f
Daptomycin, 548–549 Depressed heart, managing, 273 Dermatologic toxicity, 901
Data warehouse, 55 Dermatologic conditions, 1280–1305 Dermatomyositis, 821, 826–827
Death/dying basics of Dermatoses precipitated by infection,
brain application of structure and function to 1296–1299
critical care aspects of, 839–840 dermatoses, 1280, 1280f bacterial, 1296
neurologic states resembling, 839 morphologic approach and descriptions, infective endocarditis, 1299, 1299f, 1300f
changing goals, 4, 4t 1280, 1281t meningococcemia, 1298–1299,
combining excellence and classification of cutaneous adverse drug 1299f, 1300ft
compassion, 4–5 reactions, 1281–1284, 1283t necrotizing fasciitis, 1296–1297, 1297f
declaration of, using neurologic acute generalized exanthematous pseudomonas bacteremia, 1298, 1298f
criteria, 838 pustulosis, 1286–1287, 1287f staphylococcal scalded skin syndrome,
determination of, 128–129 adverse reactions to alternative 1297, 1298f
grief management and, 4, 4t drugs, 1286 toxic shock syndrome, 1297, 1297t
in intensive care unit, 3–5, 4t anticoagulant-induced dermatoses, Desmopressin (1-desamino-8-D-arginine
physician-assisted, 128 1285–1286, 1285f, 1286f vasopressin) (DDAVP), 946, 1127
Decerebrate posturing, 800, 800f chemotherapy-induced dermatoses, Destructive lesions, 835
Decerebrate response, 800 1284–1285, 1284t, 1285ft Detection bias, 93

Index.indd 1336 23-01-2015 15:33:51